Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC

Nivolumab, 360mg intravenous infusion (ivgtt.), on DAY1, Q3W for two cycles;

80 mg/m2 on DAY2 with paclitaxel, Q3W or 80 mg/m2 on DAY1, Q3W ivgtt for two cycles

175 mg/m2 on DAY2, with cisplatin Q3W, ivgtt for two cycles

800 mg/m2 on DAYS1-5 with cisplatin, Q3W for two cycles

4-6 weeks after neoadjuvant therapy.